Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10731119 | 0.82 | DHFR (0.49) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL7716578 | 0.78 | PLA2G7 (0.48) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL11003535 | 0.77 | DHFR (0.44) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL11318650 | 0.74 | DHFR (0.75) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Trimethoprim SCHEMBL2637561 | 0.73 | DHFR (1.00) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Trimethoprim SCHEMBL29462189 | 0.73 | DHFR (1.00) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Trimethoprim SCHEMBL24506 | 0.73 | DHFR (1.00) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL5202767 | 0.73 | PDE3B (0.47) | — | |
| SCHEMBL31685547 | 0.72 | RECQL (0.53) | MEN1ALDH1A1KMT2AHSD17B10SMN1; SMN2 | |
| Trimethoprim SCHEMBL1236697 | 0.72 | DHFR (0.97) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121574109-A | Novel organic metal bromide iron bomb material and preparation method and application thereof | 郑州轻工业大学 | 2026-02-27 | — | — | CN | disclosed |
| US-12378537-B2 | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs | CODEXIS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON | 2025-04-03 | — | — | US | disclosed |
| CN-118087393-A | One-step paving forming method for bridge deck concrete of large-span and wide-width steel-concrete composite beam | 广西路建工程集团有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-220831901-U | Self-heating cigarette | 湖北中烟工业有限责任公司 | 2024-04-26 | — | — | CN | disclosed |
| US-11874034-B2 | Heat exchanger | DAIKIN INDUSTRIES, LTD. (JP) | 2024-01-16 | — | — | US | disclosed |
| US-11828688-B2 | Aerosol matter collection device | MATIV HOLDINGS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| EP-3578557-B1 | CHEMICAL PROCESS FOR PREPARING SPIROINDOLONES AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2023-09-20 | — | — | EP | disclosed |
| WO-2023141242-A1 | SYSTEMS AND METHODS FOR IDENTIFYING MUTANTS | BIOMETIS TECHNOLOGY, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| CN-219125364-U | Cigarette paper and heating cigarette | 湖北中烟工业有限责任公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-4149304-A1 | AEROSOL MATTER COLLECTION DEVICE | SWM Luxembourg (LU) | 2023-03-22 | — | — | EP | disclosed |
| EP-4125945-A1 | ENTERIC NITRERGIC NEURONS AND METHODS OF USING THE SAME | The Regents of the University of California (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4041397-A1 | HYBRID ANTIBODY | Epsilogen Ltd (GB) | 2022-08-17 | — | — | EP | disclosed |
| EP-4041398-A1 | HYBRID ANTIBODY | Epsilogen Ltd (GB) | 2022-08-17 | — | — | EP | disclosed |
| US-6440965-B1 | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system | KRENITSKY PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | DHFR, CCNH, ODC1 | DHFR 1/4885MEN1 2382/4885SLC22A1 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.